280 related articles for article (PubMed ID: 15133634)
1. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.
Scheidhauer K; Walter C; Seemann MD
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S70-9. PubMed ID: 15133634
[TBL] [Abstract][Full Text] [Related]
2. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
[TBL] [Abstract][Full Text] [Related]
4. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
6. PET/CT and breast cancer.
Zangheri B; Messa C; Picchio M; Gianolli L; Landoni C; Fazio F
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S135-42. PubMed ID: 15133636
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
9. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
10. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
11. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results.
Heusner TA; Hahn S; Jonkmanns C; Kuemmel S; Otterbach F; Hamami ME; Stahl AR; Bockisch A; Forsting M; Antoch G
Br J Radiol; 2011 Feb; 84(998):126-35. PubMed ID: 20959375
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
18. Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI.
Jalaguier-Coudray A; Delarbre B; Brenot-Rossi I; Houvenaeghel G; Villard-Mahjoub R; Viens P; Thomassin-Naggara I
AJR Am J Roentgenol; 2016 Apr; 206(4):891-900. PubMed ID: 27003055
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
20. Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?
Bitencourt AG; Lima EN; Chojniak R; Marques EF; Souza JA; Andrade WP; Guimarães MD
Eur J Radiol; 2014 Aug; 83(8):1381-6. PubMed ID: 24931922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
